What's Actually Going Down With Tenofovir
Local treatment, which was planned for week 12, included radiation therapy, surgery, or both [12]. Of the six remaining patients who had metastasis at the time of diagnosis, three (7.7%) underwent CAV chemotherapy, one (2.6%) IE chemotherapy (2.5 g/m2/day ifosfamide, days 1�C3; 120 mg/m2/day etoposide, days 1�C3), one (2.6%) VCE chemotherapy, and one (2.6%) cisplatin (60 mg/m2/day on day 1) plus adriamycin (60 mg/m2/day on day 1) chemotherapy. The median follow-up period of the patients was 18 (range, 2�C134) months. At the end of this period, 16 patients (41%) had died, one due to the toxic effects of chemotherapy and 15 due to disease progression. The median EFS was 23 months (95% CI: 1�C64), the 1-year general EFS was 60%, and the 4-year general EFS was 48%. Gender, age, site of the primary tumor, surgery, radiotherapy, or local treatment with chemotherapy (surgery and radiotherapy, alone or in combination) did not have Tenofovir manufacturer a significant effect XAV-939 datasheet on EFS (p = 0.547, p = 0.922, p = 0.708, p = 0.111, p = 0.673, and p = 0.534, respectively). However, an osseous site of peripheral localization, limited stage, or bone metastasis correlated significantly with EFS (p = 0.005, p median OS, 1-year general OS, and 4-year general OS were 91 months (95% CI: 1�C188), 78%, and 54%, respectively. Gender, age, primary site of the tumor, or the treatment used for local control in addition to chemotherapy (surgery and radiotherapy, alone or in combination) did not have a significant effect on OS (p = 0.210, p = 0.617, p = 0.644, and p = 0.417, respectively). However, peripheral localization, limited stage, and bone metastasis did have a significant effect (p = 0.015, p tuclazepam the tumor Table 2 Statistical analysis of patients one year event free survival and overall survival according to demographic characteristic Fig. 2 Patient survival curves according to the stage of the tumor Univariate analysis revealed that central axis osseous localization had a greater effect on EFS than did a peripheral osseous localization (p
